(Q36230850)

12 August 2017

1 reference

title

The promise and challenges of bioengineered recombinant clotting factors (English)

1 reference

12 August 2017

Pipe SW

1

1 reference

PubMed ID

16102035

12 August 2017

language of work or name

1 reference

1 August 2005

1 reference

Journal of Thrombosis and Haemostasis

12 August 2017

1 reference

12 August 2017

3

1 reference

12 August 2017

8

1 reference

12 August 2017

1692-1701

1 reference

Characterization of the human factor VIII gene.

12 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Molecular cloning of a cDNA encoding human antihaemophilic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Discrepancies in potency assessment of recombinant FVIII concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Use of recombinant factor IX in subjects with haemophilia B undergoing surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Inhibitors in congenital coagulation disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Inhibitors in haemophilia: clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Influence of phospholipids on the assessment of factor VIII activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Can we improve on nature? "Super molecules" of factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

The future of recombinant coagulation factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Expression of factor VIII in recombinant and transgenic systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Coagulation factors with improved properties for hemophilia gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

New high-technology products for the treatment of haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Bioengineering of coagulation factor VIII for improved secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Purification of recombinant DNA-derived factor IX produced in transgenic pig milk and fractionation of active and inactive subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Transgenic pigs produce functional human factor VIII in milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Catabolism of the coagulation factor VIII: can we prolong lifetime of f VIII in circulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Clinical gene transfer studies for hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Spermine gates inward-rectifying muscarinic but not ATP-sensitive K+ channels in rabbit atrial myocytes. Intracellular substance-mediated mechanism of inward rectification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

A factor IX-deficient mouse model for hemophilia B gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Creation of a mouse expressing defective human factor IX

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

Thrombin generation assay and other universal tests for monitoring haemophilia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01367.X

10.1111/J.1538-7836.2005.01367.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

16102035